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105 Omalizumab – a treatment option against incipient allergic
bronchopulmonary aspergillosis when combined with severe
allergic asthma and diabetes mellitus
P. Meyer1. 1Pediatrics, University Hospital, Lund, Sweden
Objectives: Cystic ﬁbrosis (CF) patients are at risk for being colonized in their
lungs not only by bacteria but also moulds. Aspergillus fumigatus (Af) colonization
can lead to allergic sensitization against Af and severe bronchial obstruction
known as allergic bronchopulmonary aspergillosis (ABPA). The recommended
treatment against ABPA is systemic corticosteroids (CS) but is difﬁcult to use
with concomitant diabetes mellitus (DM). An alternative treatment is needed.
Methods: A 9 year old girl suffering from CF, DM, coeliac disease, severe
allergic asthma and incipient ABPA. Her asthma was poorly controlled in spite
of modern anti-asthma treatment including high dose inhaled CS and her lung
function deteriorated. Immunological markers for ABPA: Total IgE and speciﬁc
IgE were both doubled in one year to 747 kU/L and 19.2 kU/L and recombinant
Asp f 4 was 7.72 kU/L (ImmunoCAP). All together she was judged as incipient
ABPA. She started treatment with omalizumab, a humanized monoclonal anti-IgE
antibody, known to be effective against severe uncontrolled allergic asthma.
Results: She has achieved good asthma control. Serological ABPA-markers has not
increased and lung function is stable. The treatment has been without side effects.
Conclusion: Omalizumab is a treatment option against incipient ABPA, especially
when combined with DM.
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Background: Non-adherence to treatment plan is a recognised problem in CF.
Dornase alfa (DA) has been shown to improve outcomes in cystic ﬁbrosis.
Aim: To assess direct dispensing as an adherence-improving intervention and
compare dispensing rates and health outcomes to those with no intervention.
Method: Recruited patients were randomised to either direct dispensing (DD) i.e.
DA was given directly to patients in clinic or self-dispensing (SD) i.e. patients
volitionally went to pharmacy. The study period was 6 months. Records were
retrospectively accessed to determine outcomes in dispensing rates, FEV1, FVC
and BMI. Dispensing rate was used as an index of adherence.
Results: Twenty patients in the DD-group had a signiﬁcantly improved (p = 0.001)
dispensing rate from 71% during the past 6 months to 106% during the 6 months
study period. After the intervention their pick-up rate decreased (p = 0.050) to 82%.
The DD-group had a signiﬁcantly higher dispensing rate (p = 0.033) than the 19
patients in the SD-group during the study period. There was no signiﬁcant difference
in pick-up of DA in the SD-group over time. Subjects in the DD-group had a
signiﬁcantly less decline FEV1 from baseline over 300 days from the start of the
study compared to the SD-group. There was no signiﬁcant difference in FVC or
BMI between the groups.
Conclusion: Direct dispensing of DA signiﬁcantly improves pick-up rate and FEV1.
Further investigations are required in terms of behavioural changing interventions
to improve adherence long-term. Studies with larger groups are needed to identify
any correlation between improved pick-up rate and health outcomes.
Supported by: Supported by Roche Products Pty Ltd, Australia.
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The paranasal sinuses are almost regularly involved in CF. Therefore, chronic
rhinosinusitis (CRS) and nasal polyposis are hallmarks of the disease.
Recombinant Dornase alfa (rhDNase) evidently improves pulmonary outcome in
CF. Up to now, inhalative drug deposition into paranasal sinuses was substantially
limited. The novel Pari-Sinus device was shown to deliver aerosol into this segment
in cast-models and recent human scintigraphic deposition-studies.
The present DBPC cross-over pilot-trial is the ﬁrst clinical study with the device. It
was performed to evaluate primary outcome parameters and patient numbers needed
for a consecutive main study. Parameters were changes in CRS-related quality-of-
life (Sino Nasal Outcome-Test = SNOT-20) and in sinu-nasal Magnet Resonance
Imaging (MRI).
Five CF patients with CRS were included from the Jena University-CF-centre. For
each 28 days they inhaled rhDNase and NaCl0.9%, with an intermediate wash-out-
period.
Whereas placebo did not lead to comprehensible changes of SNOT-20-overall
scores, rhDNase led to a reduction of symptoms (p< 0.05). Most pronounced results
were found regarding verum-effects on factors like nasal secretion and obstruction.
In contrast, MRI results scattered widely without any trend. These limitations
of sinunasal imaging may be caused by the nasal cycle: nasal blood circulation
alternates congested and decongested sides every 2−6 hrs.
Although the small cohort does not allow assignment of statistical signiﬁcance,
promising trends are given for effectiveness of rhDNase-nebulization with the novel
device.
Supported by: Hoffmann La Roche and Pari.
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Introduction: Recent studies show that the upper airways are colonized with
bacteria of the same genotypes as found in the lower airways, indicating that a
comprehensive treatment of upper and lower airways is desirable.
This study was conducted with Colistin CF aerosolised by the SINUS pulsating
delivery system in order to estimate how much of the drug deposits in the nasal
and paranasal cavities.
Methods: Nebulization efﬁciency was investigated using a nasal cast model. This
cast is based on anatomical dimensions and is equipped with two cavities (sinuses),
each in frontal, maxillary and sphenoid position. The ostium/volume conﬁguration
of the sinuses in this study was as follows: frontal 0.5mm/7.5ml, maxillary
2mm/23ml and sphenoid 1mm/12.5ml.
Nebulisation of 3ml Colistin solution (79mg colistimethate sodium/3ml) was
conducted for 5 minutes ﬁrst into the left then 5 minutes into the right nostril
of the model, while the opponent nostril was equipped with a ﬁlter. After the
experiment the nasal cast model was dismantled and drug extracted with solvent
from the paranasal cavities, the ostia, the nasal cavity, as well as from the nebuliser
and the ﬁlter. Colistin content of these solutions was assayed by HPLC a Corona
detector.
Results: After nebulization, about 4% of the Colistin dose loaded in the nebulizer
was found in all six sinus cavities. Deposition in the single sinus cavities ranged
from 0.3‰ (frontal) up to 1.4% (maxillary). 51% of the initial drug charge remained
in the nebulizer while 6% were found in the nasal cavity and 34% were found on
the exit ﬁlter.
Conclusions: PARI SINUS can deliver nebulised Colistin CF via it’s pulsation
mode to all sinus cavities of a nasal cast model, even when the ostium diameter is
only 0.5 mm.
